Close Menu

NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA issued a draft local coverage determination yesterday stating its plans to stop covering the rheumatoid arthritis test Vectra DA and another draft proposal to extend coverage to Prolaris for patients at intermediate risk for prostate cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.